Ace the Case: 71-Year-Old Woman With IgG Lambda Multiple Myeloma at Third Relapse
Support for this activity has been provided through educational grants from Amgen, GlaxoSmithKline, Karyopharm Therapeutics, and Oncopeptides.
Click Here to Manage Email Alerts
Release date: March 9, 2022
Expiration date: March 9, 2023
Provider StatementJointly provided by
This activity utilizes a case study to discuss treatment options for multiple myeloma (MM) patients who have relapsed from previous therapies.
Joshua Richter, MD
Associate Professor of Medicine
Tisch Cancer Institute/Icahn School of Medicine at Mount Sinai
Director of Myeloma: Blavatnik Family – Chelsea Medical Center at Mount Sinai
New York, New York
This activity has been designed to meet the educational needs of hematologist-oncologists, medical oncologists, and other health care providers involved in the care of patients with MM.
Upon completion of this activity, participants should be better able to (1) distinguish between the indicated uses and mechanisms of action of current and emerging treatment regimens; (2) develop individualized management plans for MM patients based on risk and cytogenetic and genomic data.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Penn State College of Medicine designates this enduring material for 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity enables the participant to earn 0.25 Maintenance of Certification (MOC) points in the American Board of Internal Medicine’s (ABIM) MOC program. Participants who opt in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to the ACCME for the purpose of granting ABIM MOC points.
In accordance with the ACCME Standards for Integrity and Independence, all CE providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 24 months with an ineligible company whose products or services are related to the content discussed in the CE activity over which the individual has control.
All of the relevant financial relationships listed for these individuals have been mitigated. Relationship information appears below:
Joshua Richter, MD, has disclosed the following relevant financial relationships:
Speakers Bureau: Adaptive Biotechnologies, Celgene, Janssen
Consulting/Advisory Board: Adaptive Biotechnologies, AstraZeneca, Bristol Myers Squibb, Celgene, Janssen, Karyopharm, Oncopeptides, Sanofi, Secura Bio, Takeda, X4 Pharmaceuticals
Penn State College of Medicine
Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.
Multiple Myeloma Research Foundation
Mary DeRome, Director of Medical Communications and Education, has disclosed no relevant financial relationships.
Staff involved in the development and review of this activity have disclosed no relevant financial relationships.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Penn State College of Medicine, RedMedEd, the Multiple Myeloma Research Foundation, Amgen, GlaxoSmithKline, Karyopharm Therapeutics, and Oncopeptides do not recommend the use of any agent outside the labeled indications.
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Penn State College of Medicine, RedMedEd, the Multiple Myeloma Research Foundation, Amgen, GlaxoSmithKline, Karyopharm Therapeutics, or Oncopeptides. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Method of Participation
There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive CME credit for participation, participants must complete the posttest and program evaluation. Certificates can be printed immediately.
For questions regarding CME credit, contact Penn State Continuing Education at (717) 531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G6798-22-T.
A computer, iPad, iPad Mini (iPadOS 14 or higher), iPhone (iOS 14 or higher), or Android device (OS 11 or higher) with an Internet connection using one of these browsers: Chrome, Firefox, Safari, Microsoft Edge
CME credit for this activity is provided by Penn State College of Medicine. If you register for CME credit for this educational activity, RedMedEd will forward relevant personally identifiable information to the Penn State College of Medicine so that records can be maintained concerning any credits issued to you. Aggregated data concerning registrations, posttests, and evaluations may be shared, but RedMedEd will not knowingly share any personally identifiable information. The information you provide on this site may be used to contact you about your CME credit or other relevant educational activities provided through Penn State College of Medicine or RedMedEd. For more information, contact ContinuingEd@hmc.psu.edu or firstname.lastname@example.org.
© 2022. This CME-certified program is held as copyrighted by Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation. Through this notice, Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.